Boost Biopharma


Boost is the developer of AdaptVax, a platform that rapidly (<45 days) creates highly immunogenic and expressible protein vaccine antigens. This enables the rapid updating of vaccines to current viral strains, which is especially critical for SARS-CoV-2 and other emerging threats. Using AdaptVax, Boost has generated a complete library of best-in-class, next-generation SARS-CoV-2 RBD protein antigens that show exceptional results in primate studies conducted in the USA, in addition to being highly expressible, stable, and low cost (less than 10% of the cost of mRNA). Boost SARS-CoV-2 next-generation antigens are being evaluated by some of the world's leading vaccine manufacturers. We have also generated a pan-Omicron monoclonal antibody (>99.9% inhibition of RBD-ACE2 receptor binding for all BA.X variants tested, including BA.4/5, and an IC50 <0.25 nM) that is currently available for license. Boost initial patent applications were filed in June 2020, and the company is led by an experienced team of scientific and business talent. We are interested to meet with prospective partners and investors.